Video

Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC

The panel reviews clinical data and provides real-world insight on how use of PSMA-PET imaging has impacted the management of patients with prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Related Content
      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
      May 6th 2025

      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

      Hannah Clarke
      Initial study results may be available as soon as the first half of 2026.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Stephen J. Freedland, MD
      April 28th 2025

      Most men in EMBARK trial recover T levels following treatment suspension

      Benjamin P. Saylor
      More than 80% of patients in both groups had a full recovery of testosterone.
      Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
      April 26th 2025

      TikTok, social media does more harm than good for prostate cancer education

      Patrick Campbell
      Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
      © 2025 MJH Life Sciences

      All rights reserved.